Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ph 2 Double-blind, Double-dummy, Multicenter, Prospective, Rand Study of PK of LCP-Tacro™ Tablets Once Daily, Compared to Prograf® Caps, Twice Daily, for Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients

NCT01666951 is registered in ClinicalTrials.gov with Veloxis Pharmaceuticals as lead sponsor.

NCT NCT01666951
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01666951 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ph 2 Double-blind, Double-dummy, Multicenter, Prospective, Rand Study of PK of LCP-Tacro™ Tablets Once Daily, Compared to Prograf® Caps, Twice Daily, for Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients
Lead sponsor
Veloxis Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2012
Completion date
May 31, 2013
Enrollment
36 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

renal failure